Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP2 alone or with Nivolumab in advanced solid tumors
NCT04336241Phase 1Active, not recruiting
- Sponsor
- Replimune Group, Inc.
- Start
- Oct 2019
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Antibody Conjugates, Gene Silencing
- Countries
- 2
01
Overview
Phase 1, open-label trial of sturlimogene erparepvec in solid tumor, Uveal melanoma (UM), lung cancer and 3 more, sponsored by Replimune Group, Inc. Primary endpoints: Percentage of adverse events, Percentage of serious adverse events and 6 more. Started Oct 2019; status: active, not recruiting.
02
Drugs
sturlimogene erparepvec
03
Conditions
solid tumorUveal melanoma (UM)lung cancerbreast cancergastrointestinal cancer
Beyond the preview
Go deeper on NCT04336241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04336241.